You are here: Industry Insights > Symkevi

News List

Symkevi/Kalydeco cleared for use in young CF patients pharmatimes
November 30, 2020
The European Commission as approved use of Vertex' Symkevi (tezacaftor/ivacaftor) with Kalydeco (ivacaftor) for eligible children with cystic fibrosis (CF) aged 6-11 years.
NHS England calls Vertex an ‘extreme outlier’ in conduct of Orkambi negotiations pharmaceutical-technology
March 08, 2019
During a House of Commons Health and Social Care Committee witness session on the availability of Vertex’s Orkambi and other cystic fibrosis (CF) drugs on the National Health Service (NHS)
UK politicians to grill Vertex CEO over CF price drug row pharmaphorum
March 07, 2019
The CEO of Vertex Pharmaceuticals is to give evidence before influential UK politicians on Thursday, who are investigating the ongoing row over the price of cystic fibrosis drugs in England.
Vertex to submit Orkambi, Symkevi to SMC pharmatimes
December 21, 2018
Vertex has revealed that it will be submitting its cystic fibrosis medicines Orkambi and Symkevi to the Scottish Medicines Consortium for appraisal, following “constructive discussions” with the Scottish government.
Vertex wins European approval for new cystic fibrosis combination pharmaphorum
December 17, 2018
European regulators have approved Vertex’s new cystic fibrosis (CF) combination treatment Symkevi.The European Commission’s greenlight for Symkevi (tezacaftor/ivacaftor) will allow.....